RxDoctor Payments Data

Neeraj Singh, MD

Colon & Rectal Surgery · Glendale, AZNPI 1609053545

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (51.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 95.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $9,498 and has fallen 97.9% since, to $197 in 2025.

$18,502in general payments, 2019–2025

Across 71 payments — averaging $260.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$18K
  • Insmed, Inc.$125
  • AbbVie$113
  • Coloplast$110
  • Axonics, Inc.$69
  • W. L. Gore & Associates, Inc.$65
  • plus $391 from 14 others

What the payments were for

  • Speaking & faculty fees$4,90026%
  • Travel & lodging$1,7059%
  • Food & beverage$2,37113%
  • Education$9,47051%
  • Gifts$560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,502 in reported general payments places this provider in the 75th percentile of 50 colon & rectal surgery providers in Arizona.

See all colon & rectal surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$175,045
Medicare patients
418
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,550
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl121$1,861
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg56$1,162
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl48$767
Lidocaine-PrilocaineLidocaine/Prilocaine42$513
Procto-Med HcHydrocortisone25$478
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$364
Neomycin Sulfate63$356
Hydrocortisone23$347
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen35$241
Metronidazole65$119
Tramadol Hcl12$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$35$2,55016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 colon & rectal surgery providers in Arizona.

Other colon & rectal surgery in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →